Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2017-12-21 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a short press release dated December 21, 2017, announcing that ABIVAX's senior management team will participate in an investor and partnering meetings event ('Corporate Access' Event) in San Francisco from January 8-10, 2018. This is not a formal regulatory filing (like 10-K, IR, ER), nor is it a presentation (IP) or a transcript (CT). It is an announcement about management engaging with investors and partners regarding future meetings. This type of communication, which details management's schedule for meeting investors, is best categorized as general Investor Relations material. Since there is no specific code for 'Investor Meeting Schedule Announcement,' and it is not a formal report, it falls under the general regulatory/investor communication category, which is RNS (Regulatory Filings) as a fallback, or potentially related to Investor Presentation (IP) if it were the presentation itself. Given the context of management scheduling meetings for investors, it is a general corporate communication. However, since the core purpose is announcing management's availability for meetings, it is closest to general corporate/investor news. Given the options, RNS is the most appropriate fallback for non-standard, short corporate announcements that don't fit the specific financial report codes. If 'Investor Relations Announcement' were an option, it would be preferred. Based on the provided definitions, RNS serves as the best fit for this type of general corporate update/announcement.
2017-12-21 English
ABIVAX prasentiert auf der 8. internationalen Konferenz uber 'HIV Persistence During Therapy' Phase-2a-Daten, die bestatigen, dass ABX464 das HIV-Reservoir verringert
Regulatory Filings Classification · 1% confidence The document is a press release dated December 15, 2017, announcing that ABIVAX will present Phase-2a data regarding its drug ABX464 at the 8th International Conference on 'HIV Persistence During Therapy'. It details clinical trial results (reduction of HIV reservoir) and mentions the presentation is part of a plenary session at a scientific conference. This type of announcement, focusing on scientific data presentation at an external event rather than a mandatory regulatory filing (like 10-K, ER, or IR), is best classified as a general corporate news release. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific regulatory filing, and it is announcing scientific/clinical progress, it falls under the general 'Regulatory Filings' (RNS) category as a catch-all for corporate news that doesn't fit the highly specific financial/governance codes, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the context of DGAP news distribution and the nature of the content (clinical data update presented externally), RNS is the most appropriate fallback for a non-standard corporate update.
2017-12-15 German
ABIVAX prasentiert in Plenarsitzung auf der 8. internationalen Konferenz uber 'HIV Persistence During Therapy'
Regulatory Filings Classification · 1% confidence The document is a press release dated December 7, 2017, announcing that ABIVAX will present data at the 8th International Conference on 'HIV Persistence During Therapy'. It details the content of the presentation (Phase 2a study results for ABX464) and includes standard corporate boilerplate information and contact details. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement about participation in a scientific/industry conference, which is best classified as a general corporate announcement or news release. Since there is no specific category for 'Conference Presentation Announcement', and it is not a formal regulatory filing (RNS) or a presentation document itself (IP), the most appropriate category is the general Regulatory Filings (RNS) as a fallback for corporate news that doesn't fit specific financial reporting types, although it strongly resembles an Earnings Release (ER) in structure, it focuses on scientific data presentation rather than period financial results highlights. Given the context of scientific data presentation, RNS is the safest general category for non-standard corporate news.
2017-12-07 German
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated December 7, 2017, announcing that ABIVAX will present data at the 8th International Conference on HIV Persistence During Therapy. It details the focus of the presentation (ABX464 clinical trial data) and includes quotes from company personnel and contact information. This type of announcement, which publicizes participation in a scientific conference or the presentation of new data outside of a formal regulatory filing period (like an earnings release or 10-K), is best classified as a general Investor Presentation (IP) or, given its nature as a press release about scientific updates, it aligns closely with the purpose of an Investor Presentation or a general announcement. Since it is not a formal regulatory filing (like 10-K, AR, ER) but rather an announcement about presenting scientific/clinical data to investors/the scientific community, 'Investor Presentation' (IP) is the most fitting category, as these often include summaries of data to be presented. It is not a Call Transcript (CT), Earnings Release (ER), or a Report Publication Announcement (RPA) because it is the substantive announcement itself, not just a notice that a report is available.
2017-12-07 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated December 7, 2017, announcing that ABIVAX will present clinical trial data (related to drug ABX464) at the 8th International Conference on HIV Persistence During Therapy. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific/investor-related information being shared at a conference. Since it details upcoming presentations of clinical data and company pipeline updates aimed at the scientific and investment community, it most closely aligns with an Investor Presentation (IP) or a general announcement. Given the context of presenting scientific findings and clinical trial updates to the public/investors, 'Investor Presentation' (IP) is the most fitting category, even though the document itself is a press release *about* the presentation, as it conveys core investor information. However, if we strictly follow the definitions, this is an announcement of participation in a scientific conference, which doesn't perfectly match any category except perhaps RNS (Regulatory Filings) as a fallback, or IP if we interpret it as the content being presented is investor-focused. Since it is an announcement about data presentation, and not the presentation document itself, and it is not a standard regulatory filing, RNS is the safest general category for non-standard corporate announcements. Given the content is highly specific scientific/clinical data being shared, and it's not a standard financial report, RNS is appropriate as a general corporate communication.
2017-12-07 English
ABIVAX prasentiert auf dem Deutschen Eigenkapitalforum 2017
Regulatory Filings Classification · 1% confidence The document is a press release from ABIVAX announcing that its Senior Management will be giving a presentation at the 'Deutsches Eigenkapitalforum 2017' (German Equity Forum 2017). The text details the CEO's planned presentation time and location, and provides an update on the company's pipeline (ABX464 for HIV and Colitis ulcerosa, ABX196 for oncology). This content is characteristic of an announcement intended for investors regarding participation in a financial conference, which aligns best with the 'Investor Presentation' (IP) category, as it is promoting the content that will be presented to investors, or potentially a general announcement about investor relations activities. Since it is an announcement about presenting company strategy and pipeline updates to investors at a major forum, 'Investor Presentation' (IP) is the most fitting category, as it is not the presentation itself, but the announcement of the presentation and the key highlights that will be discussed. It is not a formal regulatory filing like 10-K or ER, nor is it a transcript (CT) or a formal factsheet (FS).
2017-11-22 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.